January 08, 2025 07:57 pm (IST)
Shantha's Pentavalent Pediatric Vaccine prequalified by WHO
Hyderabad, May 5 (IBNS): Sanofi Pasteur, the vaccines division of Sanofi on Monday announced that its pediatric pentavalent vaccine Shan5, developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, has received prequalification status from the World Health Organization (WHO).
This status qualifies Shan5 vaccine for purchase by United Nations agencies, mainly UNICEF.
Shan5 prequalification will give more children around the world access to the latest high-quality, fully-liquid, 5-in-1 vaccine and help secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries.
“Shan5 is the first product that puts together the best of Shantha and Sanofi Pasteur’s assets and talents,” said Olivier Charmeil, Sanofi Pasteur President and CEO.
“Today, a significant number of babies born every year do not have access to modern vaccination programs. By delivering large supplies of high-quality and affordable vaccines to emerging and low-income countries, Shantha will be contributing to filing this gap for the benefits of babies and their parents," Charmeil said.
Shan5 is produced at Shantha’s state-of-the-art manufacturing facility in Hyderabad and received Marketing Authorization in India in March 2014.
“The development of Shan5 benefitted from Sanofi Pasteur’s more than 50 years of experience with whole-cell pertussis and combination vaccines—ensuring robust processes and guaranteeing international quality standards,” said Harish Iyer, Shantha CEO at a media briefing in Hyderabad.
"Shantha’s manufacturing platform in India will serve Indian needs and provide Sanofi Pasteur access to additional vaccine markets globally," he said.
Varaprasad Reddy, Founder of Shantha Biotechnics and Non-Executive Chairman of the board shared, “It is a very happy and momentous day for all of us at Shantha. My waiting period of 4 years has ended and we are very jubilant. I want to immensely thank all the scientists of Sanofi Pasteur and Shantha Biotechnics for their collective and cooperative work together, for achieving this goal of establishing Shan5. We move forward, committed and focused to our priority and passion which is to serve people through high quality, affordable vaccines.”
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Avian flu risk still remains 'low' even after US registers first death due to H5N1 virus, says WHO
Wed, Jan 08 2025
India's HMPV cases surge to 7 after two cases reported from Nagpur
Tue, Jan 07 2025
India's health ministry confirms two HMPV cases in Karnataka
Mon, Jan 06 2025
India detects its first case of HMPV in Bengaluru
Mon, Jan 06 2025
HMPV virus outbreak: India asks WHO to share timely updates on the situation in China
Sun, Jan 05 2025
South Korea: Scientists find way to change cancerous cells back to normal without side effects
Wed, Jan 01 2025
WHO asks China to share data five years after COVID-19
Wed, Jan 01 2025